Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Docetaxel and Capecitabine in Prostate Cancer
NCT00151047Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Mar 2003
- Primary completion
- Jan 2005
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and capecitabine in prostate cancer (PCa), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Percentage of patients who respond to treatment at 6 months. Started Mar 2003; status: completed.
02
Drugs
docetaxelcapecitabine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00151047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00151047.